Bextra Facts:

Prescription nonsteroidal anti-inflammatory drugs (NSAIDs), such as Bextra (valdecoxib) are one of the leading classes of drugs that cause Stevens Johnson Syndrome (SJS), toxic epidermal necrolysis (TEN), and erythema multiforme (EM) due to drug allergy reactions. Stevens-Johnson syndrome is a rare inflammatory skin disorder that can be life-threatening - up to 27 percent of those affected incur long term eye damage or vision loss, and up to 15 percent die. The disease causes lesions in the mouth, eyes and on the body. In some cases, permanent skin damage and scarring occur. Lesions on internal organs can cause serious inflammation of the lungs, heart and kidneys.cardiovascular disease were discovered.

Pfizer first acknowledged cardiovascular risks associated with Bextra in October of 2004. The American Heart Association soon after was presented with a report indicating patients using Bextra while recovering from heart surgery were 2.19 times more likely to suffer a stroke or heart attack than those taking placebos.

On April 7, 2005, Pfizer withdrew Bextra from the U.S. market on recommendation by the FDA, citing an increased risk of heart attack and stroke and also the risk of a serious, sometimes fatal, skin reaction. This was a result of recent attention to prescription NSAIDs, such as Merck's Vioxx.

Serious safety concerns about the entire class of COX-2 inhibitors, including Bextra, have been raised due to the recent Vioxx recall.

Usage:

Bextra (Valecoxib)is a prescription drug specifically prescribed for the treatment of acute pain, symptoms of various types of arthritis including osteoarthritis, ankylosing spondylitis, and rheumatoid arthritis, in addition to severe menstrual pain and discomfort. It has also been prescribed to decrease the growth of colon polyps in those people who suffer from Familial Adenomatous Polyposis. It is classified as a nonsteroidal anti-inflammatory drug, or NSAID.Bextra is also known as a Cox-2 inhibitor. Other Cox-2 inhibitors include the prescription drugs Vioxx and Celebrex, both of which were removed from the market after links to Bextra is designed to assist in pain and inflammation relief by blocking the Cox-2 enzyme that creates prostaglandins in the body. Decreasing these prostaglandins helps the body by reducing pain and inflammation. Bextra (Valdecoxib) was manufactured and marketed under the brand name Bextra by G. D. Searle & Company. It was available by prescription in tablet form until 2005, when it was removed from the market due to concerns about possible increased risk of heart attack and stroke.

Litigation:

Lawsuits against Pfizer have already begun in the case of Bextra recall. The Bextra lawsuits claim, among other things, that Pfizer failed to adequately and properly test Bextra and failed to warn doctors, patients and others about its potential risks. Studies showed that patients who used Bextra were more likely to suffer heart attacks and stroke.

Countless individuals have already suffered severe or fatal injuries including heart attacks, strokes, embolisms, gastrointestinal bleeding, ulcers, and skin reactions such as Stevens-Johnson syndrome. This drug did not carry sufficient warnings regarding the potentially fatal side effects it can cause. If you or a loved one have been injured by and NSAID COX-2 Inhibitor like Bextra please submit the contact form at right and and experienced DrugSettlement.com attorney or representative will call you to dicuss your rights.

If you or a member of your family may have been injured as a result of a pharmaceutical drug, please contact the defective drug lawyers at the Law Office of Nix and McIntyre.

We serve clients nationwide, in Alabama (Montgomery), Alaska (Juneau), Arizona (Phoenix), Arkansas (Little Rock), California (Los Angeles, San Diego, San Francisco), Colorado (Denver), Connecticut (Hartford), Delaware (Dover), Florida (Jacksonville, Miami), Georgia (Atlanta), Hawaii (Honolulu), Idaho (Boise), Illinois (Chicago), Indiana (Indianapolis), Iowa (Des Moines), Kansas (Topeka), Kentucky (Frankfort), Louisiana (New Orleans), Maine (Augusta), Maryland (Baltimore), Massachusetts (Boston), Michigan (Detroit) Minnesota (Minneapolis), Mississippi (Jackson), Missouri (St. Louis, Kansas City), Montana (Helena), Nebraska (Lincoln), Nevada (Las Vegas), New Hampshire (Concord), New Jersey (Trenton), New Mexico (Santa Fe), New York (New York City), North Carolina (Charlotte), North Dakota (Bismarck), Ohio (Columbus, Cleveland), Oklahoma (Oklahoma City), Oregon (Portland), Pennsylvania (Philadelphia), Rhode Island (Providence), South Carolina (Columbia), South Dakota (Pierre), Tennessee (Memphis, Nashville), Texas (Dallas, Houston) Utah (Salt Lake City), Vermont (Montpelier), Washington (Seattle), Washington D.C., West Virginia (Charleston), Wisconsin (Madison) and Wyoming (Cheyenne) and their surrounding areas.